Sorafenib 200mg Tablets
Tablet belongs to the class of medicines known as tyrosine kinase inhibitors used in the treatment of liver cancer, kidney cancer, and thyroid cancer.
Sorafenib 200mg is an oral cancer medicine prescribed for specific advanced-stage liver, kidney, and thyroid cancers. As a multikinase inhibitor, it interferes with the signals tumours use to grow and form new blood vessels. Treatment is generally managed as part of a wider oncology care plan rather than used on its own.
Each Sorafenib 200mg tablet contains the active ingredient sorafenib, supplied as sorafenib tosylate. It falls under a group of cancer medicines called multikinase inhibitors, which differ from conventional chemotherapy by acting on specific proteins involved in tumour cell signalling.
This medicine is usually reserved for adults with advanced cancers where the treatment goal is to control or slow disease progression. Given its targeted mechanism and potential for side effects across multiple organ systems, Sorafenib is normally started and monitored by an oncology specialist.
Sorafenib 200mg may be prescribed to treat:
Advanced hepatocellular carcinoma (liver cancer)
Advanced renal cell carcinoma (kidney cancer) when earlier treatment options have not worked or are not appropriate
Differentiated thyroid carcinoma that continues to progress despite radioactive iodine therapy
The suitability, dosing, and duration of Sorafenib treatment should always be decided by an oncologist based on the individual's cancer type, stage, and overall health.
Sorafenib blocks a group of enzymes called kinases that cancer cells rely on to divide and spread. It also interferes with the process tumours use to build new blood vessels to feed themselves, a process known as angiogenesis. Together, these actions are intended to restrict how a tumour grows and progresses.
Because Sorafenib works by managing cancer growth rather than curing the underlying disease, its effectiveness is tracked over time through imaging and clinical review rather than judged by how a person feels in the short term.
Take Sorafenib exactly as prescribed by your healthcare professional.
Commonly taken twice a day, with doses spaced roughly 12 hours apart
Usually taken on an empty stomach, at least one hour before eating or two hours after a meal, as food can reduce absorption
Swallow tablets whole with a full glass of water; do not crush unless your doctor has advised this
Try to keep dosing times consistent from day to day
Never adjust, pause, or stop treatment on your own — oncologists sometimes deliberately interrupt or reduce Sorafenib doses to manage side effects, and this should only be done under medical guidance
If you're unsure what to do after a missed dose, contact your prescribing doctor directly, as this depends on your individual treatment schedule.
Let your doctor or pharmacist know about your complete medical history and every medicine, supplement, or herbal product you're currently taking.
Extra caution or monitoring may be required if you have:
Uncontrolled high blood pressure or existing heart conditions
A tendency to bleed easily, or if you're on blood-thinning medication
Reduced liver or kidney function
Recent or planned surgery, due to possible effects on wound healing
A personal or family history of heart rhythm abnormalities (QT prolongation)
Sorafenib's levels in the body can be affected by certain seizure medicines (including phenytoin, carbamazepine, and phenobarbital), rifampicin-type antibiotics, and St John's Wort, among other substances. This list is not exhaustive — always check possible interactions with your doctor or pharmacist before starting any new medicine.
Sorafenib is not advised during pregnancy. Animal studies and its mechanism of action suggest a risk of harm to a developing baby, so reliable contraception is generally recommended both during treatment and for some time afterward — discuss timing with your doctor.
Breastfeeding isn't generally recommended while on Sorafenib, since it isn't known whether the medicine transfers into breast milk, and a risk to a nursing infant can't be excluded. Speak to your doctor or pharmacist about family planning, contraception, or breastfeeding before starting or while on treatment.
Like all medicines, Sorafenib can cause side effects, although not everyone experiences them.
Common side effects include:
Diarrhoea
Tiredness or low energy
Hand-foot skin reaction — redness, tenderness, or peeling on the palms and soles
Dry or irritated skin, rash
Thinning hair or hair loss
Nausea or poor appetite
Increased blood pressure
Get medical help promptly if you notice chest pain, sudden breathlessness, unusual bruising or bleeding, severe skin blistering or peeling, or signs of a serious allergic reaction such as swelling of the face or throat.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Store Sorafenib according to the instructions shown on the original product packaging.
Keep tablets in their original packaging, away from moisture
Store in a dry place
Keep out of reach and sight of children
Do not use beyond the expiry date printed on the pack
It treats certain advanced-stage cancers, specifically liver, kidney, and thyroid cancers that meet particular clinical criteria.
There's no fixed timeframe — doctors typically evaluate response through periodic scans and check-ups rather than expecting a quick, noticeable effect.
It's usually best taken on an empty stomach, since eating close to a dose can lower how much of the medicine is absorbed.
It's commonly taken twice daily on a consistent schedule, roughly 12 hours apart, following your doctor's specific instructions.
Generic sorafenib contains the same active substance and is expected to perform equivalently, though tablet appearance and inactive ingredients can vary by manufacturer.
Not usually. Many side effects, including hand-foot skin reaction, are managed through temporary dose reduction or a short break in treatment, decided by your oncologist rather than by stopping permanently on your own.
In some cases, yes, but any combination therapy must be planned and supervised by a specialist due to the risk of interactions.